Accessibility Statement Skip Navigation
  • Resources
  • Blog
  • Journalists
  • +44 (0)20 7454 5110
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All Public Company News
      • All Multimedia News
      • View All News Releases

      • Regulatory News

      • D/A/CH Regulatory News
      • UK Regulatory News
      • View All Regulatory News

  • Business & Money
      • Auto & Transportation

      • Aerospace & Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads & Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking & Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers & Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalisation
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls & Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil & Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defence
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation & Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking & Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers & Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines & Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics & Personal Care
      • Fashion
      • Food & Beverages
      • Furniture & Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewellery
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks & Tourist Attractions
      • Gambling & Casinos
      • Hotels & Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Animal Welfare
      • Corporate Social Responsibility
      • Economic News, Trends & Analysis
      • Education
      • Environmental
      • European Government
      • Labour & Union
      • Natural Disasters
      • Not For Profit
      • Public Safety
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Overview
  • Distribution
  • Paid Placement
  • Multimedia
  • Disclosure Services
  • SocialBoost
  • Rooms
    • MediaRoom
    • ESG Rooms
  • AI Tools
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Hamburger menu
  • Cision PR Newswire UK provides press release distribution, targeting, monitoring, and marketing services
  • Send a Release
    • Phone

    • +44 (0)20 7454 5110 from 8 AM - 5:30 PM GMT

    • ALL CONTACT INFO
    • Contact Us

      +44 (0)20 7454 5110
      from 8 AM - 5:30 PM GMT

  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • News in Focus
    • Browse News Releases
    • Regulatory News
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
    • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • Overview
  • Distribution
  • Paid Placement
  • Multimedia
  • Disclosure Services
  • Cision Communications Cloud®
  • AI Tools
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists

COVID-19 Panic Spikes Global Demand for Injectable Benzodiazepine: Future Market Insights Study

This image opens in the lightbox

News provided by

Future Market Insights

06 Jul, 2020, 14:15 GMT

Share this article

Share toX

Share this article

Share toX

DUBAI, U.A.E, July 6, 2020 /PRNewswire/ -- Future Market Insight's projections reveal that the global injectable benzodiazepine market is set to shoot up significantly in 2020, reaching a value of US$ 260 Mn in the wake of the coronavirus pandemic.

Benzodiazepines are a class of psychoactive drugs used to reduce anxiety amongst patients. As the pandemic tightens its grip each day, stress levels among individuals regarding the threat is increasing. Massive layoffs from jobs across various industries due to lockdowns is leading to increased cases of depression. Without jobs, people are unable to sustain their families, which is putting enormous strain on their mental and physical well-being. Therefore, consumption of anti-depressant drugs containing benzodiazepine has increased.

Injectable benzodiazepine drugs are administered as the first course of treatment for bipolar disorders, dementia, schizophrenia, autism and anxiety disorders. According to the estimates provided by WHO, European College of Neuro Psychopharmacology (ECNP) and the European Brain Council (EBC), a quarter of the world's population is afflicted by mental disorders at least once in their lifetime. As a result of these increasing affliction cases, the demand for injectable benzodiazepine drugs is set to increase in the long-run.

"Rising prevalence of generic injectable drugs has provided major traction to the injectable benzodiazepine market since the past few years and will continue to do so during the forecast period. However, stringent government regulations concerning drug dosage has led to a limited number of formulations being listed under the "branded" category, thus limiting market penetration," concludes a prominent FMI analyst.

For more insights into the Market, request a sample of this report@ https://www.futuremarketinsights.com/reports/sample/rep-gb-11724

Key Takeaways from the Global Injectable Benzodiazepine Market Report

  • Short-action injectable benzodiazepine drugs is gaining ground attributed to immediate action and fast excretion
  • Generic injectable benzodiazepine drugs are stealing the spotlight as they are more cost-effective. Generic midazolam, diazepam and lorazepam drugs are being prescribed for insomnia, anxiety and seizures on an increased frequency
  • A CAGR of ~3% is predicted for the global injectable benzodiazepine drugs market for the year 2020 due to rising stress levels associated with COVID-19
  • Europe and North America shall jointly capture approximately 3/5th of the global injectable benzodiazepine market by 2020-end

Global Injectable Benzodiazepine Market- Key Trends

  • Leading manufacturers are concentrating on addressing drug shortages and reach a wider target audience. For this, optimizing production and effective cost management are necessary
  • Rising prevalence of mental disorders in the Asia-Pacific region is expected to bolster prospects of the global injectable benzodiazepine market. This is primarily due to the large population base and subsequent entry of prominent manufacturers
  • Sedentary lifestyles world over have led to a general increase in anxiety levels among people. This is also led to the outbreak of several lifestyle diseases. Taking cognizance of this fact, manufacturers are accelerating the production of injectable benzodiazepines

Global Injectable Benzodiazepine Market- Region-wise Analysis

  • Asia-Pacific shall emerge as the hotspot for injectable benzodiazepine production. Rising proliferation of mental disorders has motivated market players to establish base in the region
  • Latin America is emerging as an important market due to high incidences of alcohol withdrawal induced anxiety disorders among the population
  • MEA and Oceania are still experiencing the growth phase
  • The US shall account for nearly 3% market growth in 2020 due to the debilitating impact of the coronavirus pandemic

For any queries linked with the report, ask an analyst@ https://www.futuremarketinsights.com/ask-the-analyst/rep-gb-11724

Global Injectable Benzodiazepine Market- Competitive Landscape

The global injectable benzodiazepine market is consolidated, dominated by the following market players: Akorn Inc, Pfizer Inc., AdvaCare Pharma, Dash Pharmaceuticals LLC, Accord Healthcare Ltd, Hameln Pharma Ltd., F Hoffmann-La Roche Ltd, Hikma Pharmaceuticals, Teva Pharmaceutical Industries Ltd., Intas Pharmaceuticals Limited, Sun Pharmaceuticals Ltd, Martin Dow, Taj Pharmaceuticals Ltd. and Troy Laboratories Pty Ltd.

Besides these players, there are also other players who concentrate on inorganic growth such as forging distribution agreements, acquisition of new technology, product enhancements and partnerships with other players. For instance, Xeris Pharmaceuticals announced positive outcomes of their Phase 1b clinical trial on diazepam intramuscular injection using the XeriSol technology.

Similarly, in December 2019, Eton Pharmaceuticals Inc. announced the commercial availability of Biorphen to treat hypertension.

Global Injectable Benzodiazepine Market Taxonomy

Drug Class

  • Diazepam
  • Lorazepam
  • Midazolam

Time of Action

  • Short Acting
  • Long Acting

Indication

  • Agitation & Aggression
  • Anxiety
  • Alcohol Withdrawal
  • Muscle Spasm
  • Seizures
  • Tetanus
  • Sedation
  • Anesthesia
  • Insomnia
  • Status Epilepticus

Distribution Channel

  • Hospitals
  • Ambulatory Surgical Centers
  • Diagnostics Centers

Region/Country

North America

  • U.S
  • Canada

Latin America

  • Mexico
  • Brazil
  • Chile
  • Peru
  • Others

Europe

  • EU-5
  • Nordic countries
  • BENELUX
  • Russia
  • Poland

East Asia

  • China
  • Japan
  • South Korea

South Asia

  • India
  • ASEAN

Oceania

  • Australia
  • New Zealand

Middle East & Africa

  • GCC
  • Northern Africa
  • Southern Africa

We offer tailor-made solutions to fit your requirements, request customization@ https://www.futuremarketinsights.com/customization-available/rep-gb-11724

More about the Global Injectable Benzodiazepine Market Report

Future market insights offer a unique perspective and actionable insights on the injectable benzodiazepine market in its latest study, presenting historical demand assessment from 2015 – 2019 and projections from 2020–2030 based on drug class (diazepam, lorazepam, and midazolam), by time of action (short acting long acting), by indication (agitation & aggression, anxiety, alcohol withdrawal, muscle spasm, seizures, tetanus, sedation, anesthesia insomnia, and status epilepticus), by distribution channel (hospital pharmacies, retail pharmacies and online pharmacies) in seven key regions.

Explore Extensive Coverage about FMI's Healthcare, Pharmaceuticals and Medical Devices Landscape

Contrast Media Injectors Market: FMI's extensive research report on the contrast media injectors market offers global industry analysis for 2015-2019 and opportunity assessment for 2020-2030 and profiles the market by product type and end-users across seven key regions.

Protein A Resins Market: Investigate FMI's recent projections on the protein A-resins market to glean detailed information about key recommendations to market players on winning imperatives and successful strategies to consolidate a foothold within the market.

Generic Injectables Market: The global generic injectables market is slated to expand threefold by 2029, concludes FMI's research report published on the subject. The analysis has been provided across five segments in seven major regions.

About Future Market Insights (FMI)

Future Market Insights (FMI) is a leading provider of market intelligence and consulting services, serving clients in over 150 countries. FMI is headquartered in London, the global financial capital, and has delivery centers in the U.S. and India. FMI's latest market research reports and industry analysis help businesses navigate challenges and take critical decisions with confidence and clarity amidst breakneck competition. Our customized and syndicated market research reports deliver actionable insights that drive sustainable growth. A team of expert-led analysts at FMI continuously track emerging trends and events in a broad range of industries to ensure that our clients prepare for the evolving needs of their consumers.

Contact

Mr. Abhishek Budholiya
Unit No: AU-01-H Gold Tower (AU), Plot No: JLT-PH1-I3A,
Jumeirah Lakes Towers, Dubai,
United Arab Emirates
MARKET ACCESS DMCC Initiative
For Sales Enquiries: sales@futuremarketinsights.com 
For Media Enquiries: press@futuremarketinsights.com

Market Report: https://www.futuremarketinsights.com/reports/injectable-benzodiazepine-market

Press Release Source: https://www.futuremarketinsights.com/press-release/injectable-benzodiazepine-market

Logo: https://mma.prnewswire.com/media/1197648/FMI_Logo.jpg

Modal title

Also from this source

Isoprene Rubber Latex Market is Projected to Expand at a CAGR of 8.1% between 2024 and 2034 | Future Market Insights, Inc.

Isoprene Rubber Latex Market is Projected to Expand at a CAGR of 8.1% between 2024 and 2034 | Future Market Insights, Inc.

The isoprene rubber latex industry is predicted to be valued at USD 922 million by 2024. The market valuation is estimated to be USD 2,005.3 million...

Growing Demand for Premium Distilled Agave-based Beverages to Propel Mezcal Market at a CAGR of 14.2% by 2034 | Future Market Insights, Inc.

Growing Demand for Premium Distilled Agave-based Beverages to Propel Mezcal Market at a CAGR of 14.2% by 2034 | Future Market Insights, Inc.

According to Future Market Insights (FMI), the global mezcal market demand is estimated to reach a valuation of USD 635 million by 2024. Over the...

More Releases From This Source

Explore

Medical Equipment

Medical Equipment

Health Care & Hospitals

Health Care & Hospitals

Medical Pharmaceuticals

Medical Pharmaceuticals

News Releases in Similar Topics

Contact PR Newswire

  • +44 (0)20 7454 5110
    from 8 AM - 5:30 PM GMT
  • General Enquiries
  • Media Enquiries
  • Partnerships

Products

  • Content Distribution
  • Multimedia Services
  • Disclosure Services
  • Cision Communications Cloud®

About

  • About PR Newswire
  • About Cision
  • Partnering Opportunities
  • Careers
  • APAC
  • APAC - Simplified Chinese
  • APAC - Traditional Chinese
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Indonesia
  • Israel
  • Japan
  • Korea
  • Mexico
  • Middle East
  • Middle East - Arabic
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United States
  • Vietnam

My Services

  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
  • Data Privacy

Do not sell or share my personal information:

  • Submit via Privacy@cision.com 
  • Call Privacy toll-free: 877-297-8921

Contact PR Newswire

Products

About

My Services
  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
+44 (0)20 7454 5110
from 8 AM - 5:30 PM GMT
  • Terms of Use
  • Privacy Policy
  • Information Security Policy
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 PR Newswire Europe Limited. All Rights Reserved. A Cision company.